INCY
USDIncyte Corp. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$101.360
Kõrge
$103.860
Madal
$100.020
Maht
2.74M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
20.2B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.00M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated
Incyte to Present at Upcoming Investor Conferences
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84
RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.